Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396756 | 0.95 | KMT2A (0.48) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2421220 | 0.94 | MAPK9 (0.54) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2428331 | 0.94 | KMT2A (0.51) | KMT2AMEN1MAPK9MAPK10POLB | |
| SCHEMBL2420301 | 0.93 | MAPK9 (0.51) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL6432690 | 0.93 | MEN1 (0.52) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2426626 | 0.93 | MEN1 (0.56) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL3480189 | 0.92 | MEN1 (0.51) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2421181 | 0.92 | MEN1 (0.49) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2422685 | 0.91 | KMT2A (0.49) | KMT2AMEN1MAPK9MAPK10MAPT | |
| SCHEMBL2419239 | 0.91 | MAPT (0.48) | KMT2AMEN1MAPK9MAPK10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | claimed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8012995-B1 | Pharmaceutically active sulfonamide derivatives | MERCK SERONO SA (CH) | 2011-09-06 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
| EP-1218374-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | KMT2A 2086/4885MEN1 4590/4885MAPK9 33/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | KMT2A 2101/4885MEN1 3205/4885MAPK9 2768/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | KMT2A 3013/4885MEN1 1582/4885MAPK9 36/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885MAPK9 49/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | KMT2A 1484/4885MEN1 4390/4885MAPK9 35/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885MAPK9 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.